Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

Loehrer, 1992, A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study, J Clin Oncol, 10, 1066, 10.1200/JCO.1992.10.7.1066 von der Maase, 2005, Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer, J Clin Oncol, 23, 4602, 10.1200/JCO.2005.07.757 Bellmunt, 2014, Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 25, iii40, 10.1093/annonc/mdu223 Bellmunt, 2009, Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract, J Clin Oncol, 27, 4454, 10.1200/JCO.2008.20.5534 Choueiri, 2012, Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer, J Clin Oncol, 30, 507, 10.1200/JCO.2011.37.7002 Sankin, 2017, The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: what lies beneath the tip of the iceberg, PD-L1, Urol Oncol Bellmunt, 2017, Pembrolizumab as second-line therapy for advanced urothelial carcinoma, N Engl J Med, 376, 1015, 10.1056/NEJMoa1613683 Chen, 2013, Oncology meets immunology: the cancer-immunity cycle, Immunity, 39, 1, 10.1016/j.immuni.2013.07.012 Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011 Powles, 2014, MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, 515, 558, 10.1038/nature13904 McDermott, 2016, Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study, J Clin Oncol, 34, 833, 10.1200/JCO.2015.63.7421 Rittmeyer, 2017, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet, 389, 255, 10.1016/S0140-6736(16)32517-X Balar, 2017, Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial, Lancet, 389, 67, 10.1016/S0140-6736(16)32455-2 Rosenberg, 2016, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet, 387, 1909, 10.1016/S0140-6736(16)00561-4 Frampton, 2013, Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing, Nat Biotechnol, 31, 1023, 10.1038/nbt.2696 Chalmers, 2017, Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden, Genome Med, 9, 34, 10.1186/s13073-017-0424-2 Fehrenbacher, 2016, Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, Lancet, 387, 1837, 10.1016/S0140-6736(16)00587-0 Massard, 2016, Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer, J Clin Oncol, 34, 3119, 10.1200/JCO.2016.67.9761 Plimack, 2017, Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study, Lancet Oncol, 18, 212, 10.1016/S1470-2045(17)30007-4 Bellmunt, 2015, Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma, Ann Oncol, 26, 812, 10.1093/annonc/mdv009 Powles, 2017, Immune checkpoint inhibition in metastatic urothelial cancer, Eur Urol, 72, 477, 10.1016/j.eururo.2017.03.047 Chen, 2017, Elements of cancer immunity and the cancer-immune set point, Nature, 541, 321, 10.1038/nature21349 Motzer, 2015, Nivolumab versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 373, 1803, 10.1056/NEJMoa1510665 Castellano, 2014, Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice, BMC Cancer, 14, 779, 10.1186/1471-2407-14-779 Garcia-Donas, 2017, Lancet Oncol, 18, 672, 10.1016/S1470-2045(17)30242-5 Medioni, 2016, Efficacy and safety of vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the french multi-centre CURVE study, BMC Cancer, 16, 217, 10.1186/s12885-016-2262-9 Pistamaltzian, 2016, Treatment of relapsed urothelial bladder cancer with vinflunine: Real-world evidence by the hellenic genitourinary cancer group, Anticancer Drugs, 27, 48, 10.1097/CAD.0000000000000297 2017 2017 Carbone, 2017, First-line nivolumab in stage IV or recurrent non-small-cell lung cancer, N Engl J Med, 376, 2415, 10.1056/NEJMoa1613493